Neoadjuvant therapy for hormone receptor positive breast cancer: Challenges and advances

Brief Synopsis:

Otto Metzger, MD, will discuss controversies surrounding the appropriate use of neoadjuvant therapy for patients diagnosed with hormone receptor-positive breast cancer. He will cover: 1) patient selection, including discussions surrounding pre- versus postmenopausal women and use of genomic assays; 2) therapy options for this patient population, including chemotherapy and endocrine therapy with or without CDK4/6 inhibitors; and 3) evaluation of treatment response and the risks associated with over-interpretation of the final pathology report.